News
Gender inequalities worsen women’s access to cancer prevention and care
Researchers call for a “feminist” agenda for cancer care to eliminate gender inequality

Unequal power dynamics across society have resounding negative impacts on how women interact with cancer prevention, care and treatment, researchers have found.
According to a new Lancet Commission, gender inequality and discrimination influence women’s rights and opportunities to avoid cancer risk factors and impede their ability to seek and receive timely diagnosis and care.
Furthermore, the study found that gender inequalities have resulted in an unpaid caregiver workforce that is predominantly female, risking hindering women’s professional advancement as leaders in cancer research and policymaking, which in turn perpetuates the lack of “women-centred” cancer care.
The Commission calls for a “feminist” agenda for cancer care to eliminate gender inequality where health systems, cancer workforces and research ecosystems are more inclusive and responsive to the needs of women in all their diversities.
Dr Ophira Ginsburg, senior advisor for clinical research at the National Cancer Institute’s Center for Global Health and co-chair of the Commission, said: “The impact of a patriarchal society on women’s experiences of cancer has gone largely unrecognised.
“Globally, women’s health is often focused on reproductive and maternal health, aligned with narrow anti-feminist definitions of women’s value and roles in society, while cancer remains wholly under-represented. Our Commission highlights that gender inequalities significantly impact women’s experiences with cancer.
“To address this, we need cancer to be seen as a priority issue in women’s health, and call for the immediate introduction of a feminist approach to cancer.”
‘Women’s cancers’
A paper, published in The Lancet Global Health, estimated that 5.3 million adults under 70 years old died from cancer in 2020 and that 2.3 million of these cancer deaths were in women.
The study suggested that one and a half million premature cancer deaths in women could be prevented each year through the elimination of exposures to key risk factors or via early detection and diagnosis, while a further 800 000 lives could be saved each year if all women had access to optimal cancer care.
Approximately 1.3 million women of all ages died in 2020 due to four of the major risk factors for cancer – tobacco, alcohol, obesity, and infections, the research also showed.
The burden of cancer in women caused by these four risk factors is widely under-recognised, researchers argue. A study from 2019 found only 19 per cent of women attending breast cancer screening in the UK were aware that alcohol is a major risk factor for breast cancer.
“Discussion about cancer in women often focus on ‘women’s cancers’, such as breast and cervical cancer, but about 300,000 women under 70 die each year from lung cancer, and 160,000 from colorectal cancer: two of the top three causes of cancer death among women, globally,” said Dr Isabelle Soerjomataram, deputy branch head of cancer surveillance at IARC and co-chair of the Commission.
“Furthermore, for the last few decades in many high income countries, deaths from lung cancer in women have been higher than deaths from breast cancer.
“The tobacco and alcohol industry target marketing of their products specifically at women, we believe it’s time for governments to counteract these actions with gender-specific policies that increase awareness and reduce exposure to these risk factors.”
Greater scrutiny of the causes and risk factors for cancer in women is needed as they are less well understood compared with cancer risk factors for men, researchers have said.
There is growing evidence to suggest a link between commercial products predominantly used by women, such as certain types of breast implants, skin lighteners and hair relaxers, and an increased risk of cancer.
Dr Verna Vanderpuye, senior consultant at the Korle Bu Teaching Hospital, Ghana and co-chair of the Commission, said: “While men are at higher risk for most cancer types that develop in both sexes, women have approximately the same burden from all cancers combined, with 48 per cent of cancer cases and 44 per cent of cancer deaths worldwide occurring in women.
“Of the three million adults diagnosed with cancer under the age of 50 in 2020, two out of three were women. Cancer is a leading cause of mortality in women and many die in their prime of life, leaving behind an estimated one million children in 2020 alone.
“There are important factors specific to women which contribute to this substantial global burden.
“By addressing these through a feminist approach we believe this will reduce the impact of cancer for all,” she added.
Gender inequalities in society
Globally, women are disadvantaged in terms of education and employment opportunities and are more likely to have fewer financial resources to help cope with cancer-related financial challenges.
An analysis from eight countries in Asia found almost three-quarters of women with cancer reported catastrophic expenditures in the year following their diagnosis, with 30 per cent or more of their annual household income spent on cancer-related expenses such as medical costs and complementary medicine.
“Gender norms mean women are often expected to prioritise the needs of their families at the expense of their own health, sometimes leading to the postponement of seeking healthcare,” explained Nirmala Bhoo-Pathy, professor of epidemiology at Universiti Malaya and Queen’s University Belfast.

Sexism within healthcare systems in the form of unconscious gender biases and discrimination can lead to women receiving sub-optimal care.
Multiple studies have found women with cancer are more likely to report inadequate pain relief and be at greater risk for undertreatment of pain compared to men.
These gender biases can be intensified when the person experiencing cancer is also part of a marginalised ethnic or indigenous group or has a diverse sexual orientation or gender identity.
A recent national survey in the US found African American women of diverse sexual orientation and gender identity reported higher intersectional stigma than any other group.
Gender inequalities in society also impact the cancer workforce as well as patients and caregivers, with women significantly underrepresented as leaders.
Carolyn Taylor, founder and executive director of Global Focus on Cancer, said: “A key, yet often underestimated, part of the oncology workforce is cancer advocates who are mostly women and represent the population most affected by cancer.
“Policy makers, academic and medical institutions must fully recognise the value of patient advocates, and integrate them into all aspects of the cancer care continuum.”
A ‘feminist’ agenda
To counter the negative impact of gender inequality and transform the ways women interact with the cancer health system, the Commission argues for sex and gender to be included in all cancer-related policies and guidelines, making them responsive to the needs and aspirations of all women, whether they be patients, care providers or researchers.
The commissioners call for strategies targeted at increasing women’s awareness of cancer risk factors and symptoms, along with increasing equitable access to early detection and diagnosis of cancer.
“Our Commission exposes the asymmetries of power which influence women’s experiences of cancer and makes the recommendations required to advance an intersectional feminist approach that would reduce the impact of cancer for all,” said co-author Dr Shirin Heidari, president of GENDRO and senior researcher at Gender Centre, The Geneva Graduate Institute.
“In a society where women’s autonomy is infringed, it’s imperative that researchers, policymakers, organisations and healthcare providers do all they can to meet women’s diverse and unique needs during their experiences of cancer care.”
Dr Monica Bertagnolli, director of the National Cancer Institute, who was not involved in the Commission, said: “Achieving gender equality in the context of cancer research and care will require broad implementation of the recommendations in The Lancet Commission on women, power, and cancer, including the overarching priority action that sex and gender be included in all cancer-related policies and guidelines so that they are responsive to the needs and aspirations of women in all of their diversities.
“This is something that we can and should all support. Improved outcomes for women translate into benefits for households, communities, societies, and the world.”
Diagnosis
Where women live may influence ovarian cancer survival, especially among Black women – study

Women living in socially vulnerable neighbourhoods had a 20 per cent higher risk of death after an ovarian cancer diagnosis, a study found.
Black women also faced a 45 per cent higher risk of death than white women.
Researchers said the combination of being Black and living in a highly vulnerable neighbourhood was linked to a greater risk of death than would be expected from either factor alone.
Francesmary Modugno, professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of Pittsburgh and senior author, said: “We expected residential context to influence outcomes, but what surprised us was how much stronger the impact was for Black women.
“Our findings suggest that it’s not simply where someone lives. The interaction between a woman’s lived experience and her residential environment may be helping drive these persistent disparities.”
Modugno is part of the Women’s Cancer Research Center, a collaboration between UPMC Hillman Cancer Center and Magee-Womens Research Institute.
Epithelial ovarian cancer is the deadliest form of gynaecological cancer, with around half of patients surviving for five years after diagnosis.
Survival is lower among Black women, with fewer than 40 per cent alive five years after diagnosis.
Differences including age at diagnosis, cancer stage and tumour type explain some of the survival gap, but researchers said a substantial proportion remains unexplained.
Researchers examined whether social determinants of health, including conditions in the communities where patients live, could help explain the remaining difference in outcomes.
The study, carried out with researchers at the University of Alabama at Birmingham, analysed data from 2,544 women diagnosed with epithelial ovarian cancer and treated at the O’Neal Comprehensive Cancer Center.
The group included 509 Black women and 2,035 white women.
Researchers linked patients’ residential census tracts to the US Centers for Disease Control and Prevention’s Social Vulnerability Index.
The index measures neighbourhood factors including poverty, housing conditions, transport access, educational attainment and other socioeconomic challenges.
Black women in the study were more likely to live in highly vulnerable neighbourhoods.
However, where women lived did not fully explain the racial difference in survival.
Black women had poorer survival than white women even when they lived in similarly advantaged communities, while being Black and living in a highly vulnerable neighbourhood together was associated with a greater risk of death than expected from either factor alone.
Researchers said the findings could help health systems and cancer services identify women at greater risk and provide additional support.
Possible measures include patient navigation programmes, transport assistance, childcare support and survivorship services to help patients complete treatment and manage the challenges of cancer care.
Rebecca Arend, associate professor of gynaecology oncology at the University of Alabama at Birmingham, said: “Our findings reinforce that we must better understand and address the barriers patients face in their communities and ensure that every woman has equitable access to high-quality care.”
Arend, who is also associate director of clinical research at the O’Neal Comprehensive Cancer Center, added: “Translating research into meaningful improvements in cancer outcomes is only possible through strong collaborations among academic medical centres, researchers and community partners.”
The study builds on research published in 2025 led by Modugno and University of Pittsburgh colleagues using data from UPMC Hillman Cancer Center in western Pennsylvania.
That research also found an association between social vulnerability and ovarian cancer survival.
The latest analysis included a substantially larger group of Black women and examined more closely how residential conditions might contribute to racial inequalities in outcomes.
Researchers said the findings need to be replicated in other parts of the US and among additional racial and ethnic groups to determine how widely they apply.
Future work will examine other social and environmental factors that could affect ovarian cancer survival, including neighbourhood pollution, access to food and community resources.
Researchers hope the findings could lead health systems to develop more targeted support for patients at greatest risk of poor outcomes.
Adding neighbourhood measures such as the Social Vulnerability Index to cancer care planning could help health systems identify women facing barriers to care and connect them with support during treatment.
News
Women with endometriosis face 46% higher risk of type 2 diabetes – study

Women with endometriosis had a 46 per cent higher risk of developing type 2 diabetes than those without the condition in a recent study.
The study followed data from nearly 3m women over 25 years and was described as the largest to date examining the relationship between the two conditions.
Maggie Fuzak Nunziato, a doctoral student in epidemiology at George Mason, led the research with Anna Pollack, professor of global and community health.
Researchers found that diabetes risk varied across different forms of endometriosis, suggesting the condition may have broader long-term health implications than previously recognised.
They believe chronic inflammation associated with endometriosis may play a role in metabolic health, although more research is needed to understand the connection.
Fuzak Nunziato, the study’s lead author, said: “Previous studies largely evaluated endometriosis as a single condition and generally reported little or no overall association with type 2 diabetes.
“Our findings add to a growing understanding that endometriosis may affect more than reproductive health alone.”
The association was strongest among premenopausal women and women without obesity, groups not traditionally considered to be at the highest risk of type 2 diabetes.
Endometriosis affects around one in 10 women of reproductive age.
It occurs when tissue similar to the lining of the uterus grows outside the uterus and can cause chronic pelvic pain, infertility and other complications.
If the findings are confirmed by further research, they could help clinicians identify women with endometriosis who may be at higher risk of type 2 diabetes and could benefit from earlier screening or prevention efforts.
Researchers analysed health records from nearly 3m women in the Utah Population Database between 1996 and 2021, including almost 100,000 who had been diagnosed with endometriosis.
Some forms of endometriosis had a much stronger association with diabetes than others.
The strongest link was found among women with extra-pelvic endometriosis, meaning the condition is found outside the pelvis.
The researchers stressed that the findings show an association and do not prove that endometriosis causes type 2 diabetes.
They said further research is needed to understand the biological mechanisms connecting the two conditions and whether earlier metabolic screening could improve outcomes for women with endometriosis.
Hormonal health
We are wrapping our children in plastic and calling it care

By Ciara Donlon, founder & CEO of MOSS
A baby is born.
In the first hours of their life, before they have tasted food, before they have felt sunlight, before they have learned the sound of their own name, they are wrapped in a nappy.
That nappy, in most cases, is made from plastic, synthetic polymers, and wood pulp sourced from trees that took decades to grow.
It will be used for two hours. It will sit in landfill for five hundred years plus.
We do this up to eight times a day. For three years. For every baby born.
I have spent the better part of my adult life working with bamboo, not as a founder chasing a trend, but as someone who has watched this material perform under the most demanding conditions imaginable.
Before MOSS, I built THEYA Healthcare, one of Ireland’s first femtech companies, pioneering bamboo-based care for women undergoing breast cancer treatment, backed by clinical trials from UCD (University College Dublin).
When I turned to what came next, the answer was staring at me from every buggy on the street.
We are living through a crisis our children will inherit entirely. Conventional nappies are the third largest single-use plastic item in household waste.
An estimated three hundred million go to landfill every year.
The tree-derived wood pulp in their absorbent cores is responsible for the destruction of one billion trees annually, and the plastic components that make them leak-proof make them essentially indestructible once discarded.
A child who goes through approximately 6,000 nappies in three years generates a legacy of waste that will outlast not just them, but generations to come.
I am not writing this to make parents feel guilty. Parents are doing the very best they can. I am writing this because the industry has not given them a genuine alternative, and I believe that is something we have a responsibility to change.
MOSS was built on one question: what would a nappy look like if it were designed entirely around what was best for the baby’s skin and best for the planet they will grow up in?
The answer was bamboo, and I say that not from instinct, but from evidence.
Through THEYA’s research at University College Dublin, bamboo viscose fibre was tested against cotton across every performance metric that matters for fabric worn against the most sensitive skin.
In antibacterial testing, bamboo resulted in a 97 per cent reduction in tested bacteria. Cotton produced a 0 per cent reduction. In absorbency and breathability testing, bamboo outperformed cotton and all leading competitor products.
When I turned to nappies, manufacturer testing confirmed what the clinical evidence had shown.
MOSS’s bamboo absorption core matches or outperforms conventional wood pulp cores on every performance measure: faster second-cycle absorption, significantly less rewet against the skin, and higher total absorption capacity across every size.
In the MOSS parent product trial: 88 per cent of parents felt their baby was drier, 93 per cent found them softer, 73 per cent reported fewer leaks, and 87 per cent said they would recommend MOSS.
Bamboo is 59 per cent more absorbent than cotton. Ten times more bamboo can be grown per square metre.
It requires no irrigation, no pesticides, no insecticides, no synthetic inputs, while cotton accounts for nearly 30 per cent of global pesticide and insecticide sales and needs 20,000 litres of water to produce a single T-shirt.
Bamboo sequesters five times more carbon per hectare than most trees, regenerates from its own root system without replanting, and harvesting it does not kill the plant.
What that means in practice: a softer material better for the health of the baby’s skin, proven to reduce bacterial load and regulate temperature, is also the most sustainable choice available.
These are not competing priorities. They are the same priority.
We are the only nappy brand in Europe that does not require a single tree to be cut down for production.
MOSS nappies contain no tree-derived pulp, no PFAS, no fragrance, no alcohol, no bleach. They are between 60-100 per cent bamboo.
THEYA Healthcare was recognised by the Cartier Women’s Initiative Awards for its work at the intersection of materials science, sustainability, and women’s health.
That recognition mattered less than what it signified: designing for the people the industry had left behind is not a niche. It is the future.
When I turned to nappies, I brought the same lens. Who is being left behind?
Two groups: the baby, whose skin deserves a material free from synthetic chemicals; and the planet, which cannot absorb another generation of single-use plastic waste at current volumes.
MOSS exists for both of them.
I think often about what it means to build something for babies in 2026. These children will live into the 2100s.
The decisions we make in the next decade, about materials, about what we choose to manufacture and what we choose to discard, will shape the world they inherit in ways that are difficult to overstate.
One nappy brand will not solve the climate crisis. But founders have a responsibility to ask harder questions, to look at an industry built on cheap plastic and ask: does it have to be this way?
It does not.
What I found when I went looking was that the sustainable choice was also the better choice for the baby. Bamboo is softer than cotton. More absorbent. Naturally antibacterial, temperature-regulating, and proven to support skin health at a clinical level.
The product that was better for the planet turned out to be better for the child wearing it.
I built MOSS because I believe that the standard of care we offer newborns, in the materials we choose, the ingredients we exclude, should be as considered as every other decision a parent makes.
And because when parents are given a genuine choice, they will make it.
We owe it to them to make that choice available. We owe it, even more, to the children and future generations.
About the author
Ciara Donlon is a multi award-winning entrepreneur with nearly 30 years of experience in corporate strategy, e-commerce, and medical devices.
She is the Founder & CEO of MOSS and the founder of THEYA Healthcare, one of Ireland’s first femtech companies. THEYA’s bamboo fabric research was conducted at University College Dublin in conjunction with four Dublin teaching hospitals. Ciara is a Cartier Women’s Initiative laureate for Europe.
After a decade working in e-commerce in the corporate world, in 2010, Ciara transitioned to entrepreneurship, founding a lingerie business inspired by her interactions with breast cancer survivors, revealing a gap for non-toxic underwear for women undergoing treatment.
This led to Theya Healthcare, where she pioneered bamboo-based post-surgical innovations, backed by clinical research and protected by global patents.
Under her leadership, Theya gained international acclaim for its innovative approach to comfort and safety.
Now, as CEO of MOSS, she is transforming the baby care market, driven by a simple belief: that the everyday essentials of parenthood should give parents genuine peace of mind and protect babies, without compromising their health or the planet.
MOSS publicly launches 5th October 2026. Founding Members can register from 7th September at mossnappies.com
News5 days agoUK femtech investment surges 194% in a decade, research finds
Insight2 weeks agoNatural Cycles receives sixth FDA clearance for fertility algorithm
Wellness1 week agoCancer patient receives ‘landmark’ treatment in world-first
Insight2 weeks agoExperimental treatment significantly slows progression of fatal brain disease in women, study finds
Sponsored Content2 weeks agoThe room is filling up at WHW Europe 2026 with super early bird pricing ending this Friday
Entrepreneur6 days agoTidalSense raises £14m to expand five-minute COPD test across NHS
News5 days agoCross-Border Impact Ventures raises US$58m for women and children’s health
Cancer2 weeks agoJohnson & Johnson offers to pay US$5.5bn to settle talc cancer lawsuits












